Search
Fosun Pharma Awards Global Development, Production, and Commercialization Rights for Investigational Drug XH-S004 to Expedition
6 day ago /
Read about 0 minute
Author：小编
Fosun Pharmaceutical Industries, a holding subsidiary of Fosun Pharma, has bestowed upon Expedition the exclusive rights to develop, produce, and market its proprietary small molecule oral DPP-4 inhibitor, XH-S004, across the globe, with the exception of China, Hong Kong, and Macau. This landmark agreement will commence on August 11, 2025. Pursuant to the terms of the agreement, Expedition is obligated to make an initial payment of up to US$120 million, followed by developmental and regulatory milestone payments, as well as sales milestone payments potentially amounting to US$525 million. Additionally, Expedition will be subject to royalty payments as outlined in the agreement.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
